Clinical Trials on Active Melanoma Brain Metastases in South Africa

Total 51 results

GlaxoSmithKline

Terminated

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Melanoma and Brain Metastases

United States, Australia
HUYABIO International, LLC.
Bristol-Myers Squibb

Recruiting

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma | Progressive Brain Metastasis

Spain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
GlaxoSmithKline

Completed

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain (Break MB)

Melanoma and Brain Metastases

Australia, Germany, United States, Canada, Italy, France
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Melanoma and Brain Metastases

Canada, United States, Australia, France, Germany, Italy, Spain
Melanoma Institute Australia

Withdrawn

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases (INTRANS)

Melanoma | In-Transit Metastasis of Cutaneous Melanoma

Australia
Melanoma Institute Australia
Bristol-Myers Squibb; Melanoma and Skin Cancer Trials Limited

Active, not recruiting

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

Melanoma | Brain Metastases

Australia
Melanoma and Skin Cancer Trials Limited
University of Oxford; Trans Tasman Radiation Oncology Group

Active, not recruiting

Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma (WBRTMel)

Metastatic Melanoma

Norway, Australia, United Kingdom
Pfizer

Terminated

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)

Brain Metastases

United States, Belgium, Australia, Argentina, Italy
Royal Adelaide Hospital

Completed

A Trial Comparing Radiosurgery With Surgery for Solitary Brain Metastases

Neoplasm Metastasis | Brain Neoplasm

Australia
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases

Malignant Melanoma

Spain, United States, Canada, Germany, Netherlands, France, Italy, United Kingdom, Israel, Australia
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
PDL BioPharma, Inc.

Completed

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Melanoma | Metastases

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

Metastatic Cancer | Melanoma (Skin)

United States
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology; NRG Oncology

Recruiting

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Brain Metastases

Canada, United States
St George Hospital, Australia

Completed

Brain Metastases Study: Radiotherapy Fractionation Schemes in the Treatment of Brain Metastases

Neoplasm Metastasis | Brain Neoplasms

Australia
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma

United States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
Nektar Therapeutics

Completed

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)

Breast Cancer | Metastasis

United States, Australia, Belgium, Canada, France, Israel, Italy, Portugal, Spain, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Genentech, Inc.

Terminated

Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

Brain Metastases | Radionecrosis

United States, Canada
Leiden University Medical Center
University of Zurich; University Hospital, Bonn; NHS Lothian; Medical Center Haaglanden and other collaborators

Recruiting

Revision of the EORTC QLQ-BN20 Questionnaire (QLQBN20)

Glioma | Brain Metastases, Adult

Netherlands
Immune Design
Merck Sharp & Dohme LLC

Completed

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Melanoma - Currently Enrolling | Non-small Cell Lung Cancer - Enrollment Completed | Sarcoma - Enrollment Completed

United States
Bristol-Myers Squibb

Completed

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Melanoma | Metastases

United States, Canada, Netherlands, United Kingdom, Germany, Chile, Belgium, France, South Africa, Argentina, Brazil, Hungary, Switzerland
Novartis Pharmaceuticals

Completed

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Neoplasms, Breast

Spain, Canada, United States, Australia, Austria, Italy, Japan, Poland, Sweden, France, Germany, Switzerland, Taiwan, United Kingdom, Belgium, Greece, India
GlaxoSmithKline

Terminated

Brain Metastases In ErbB2-Positive Breast Cancer

Neoplasms, Breast

United States, Spain, Israel, Canada, Germany, Belgium, Austria, Sweden, Greece, France, Italy
Nanobiotix

Recruiting

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Metastatic Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Radiotherapy | Immunotherapy | Microsatellite Instability-High Solid Malignant Tumour | Metastasis From Malignant Tumor of Liver | Metastasis From Malignant Tumor of Cervix | Metastasis From Malignant Melanoma of Skin (Disorder) and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Sarcoma | Kidney Cancer | Ovarian Cancer | Metastatic Cancer | Melanoma (Skin)

United States, Australia, Peru, Puerto Rico
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis

Neoplasm Metastasis | Brain Neoplasms

Japan
NovoCure GmbH

Active, not recruiting

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

United States, China, Israel, Spain, Austria, Canada, Hong Kong, Germany, France, Bulgaria, Croatia, Hungary, Italy, Poland, Serbia
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy (HYPOGRYPHE)

Melanoma | Renal Cell Carcinoma | NSCLC | SCLC | Breast Carcinoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Brain Metastases, Adult

United States
Quadriga Biosciences, Inc.
Novotech (Australia) Pty Limited

Completed

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Melanoma | Sarcoma | Kidney Cancer | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Astrocytoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Thymic Carcinoma | Lung Cancer | Prostate Cancer | Brain Cancer | Cholangiocarcinoma | Bladder Cancer | Liver Cancer | Brain Metastases | Tongue Cancer | Esophagus... and other conditions

Australia
GlaxoSmithKline

Completed

Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer

Lung Cancer, Non-Small Cell

United States, Slovakia, Russian Federation, Hungary, Canada, Poland
Pharmacyclics LLC.

Completed

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm

United States, France, Belgium, Germany, Canada, Netherlands, Austria, Australia
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases

Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific

United States
Trans Tasman Radiation Oncology Group

Recruiting

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)

Metastatic Non Small Cell Lung Cancer

Australia, Singapore
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

Metastatic Cancer

United States, Canada
Spectrum Pharmaceuticals, Inc

Completed

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Metastatic Cancer

France, United States, Canada, Belgium, Italy, Australia, United Kingdom, Germany, Hungary
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Metastatic Malignant Neoplasm in the Brain

United States
NRG Oncology
National Cancer Institute (NCI)

Completed

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

Cognitive Impairment | Metastatic Malignant Neoplasm in the Brain | Solid Neoplasm

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases

Metastatic Cancer | Radiation Toxicity | Cognitive/Functional Effects

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Cognitive/Functional Effects

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Melatonin and Radiation Therapy in Treating Patients With Brain Metastases

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Radiation Toxicity

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | HER2-Positive Breast Carcinoma

United States, Korea, Republic of, Canada
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma | Metastatic BRCA-Associated Breast Carcinoma

United States, Puerto Rico
Boehringer Ingelheim

Completed

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Stroke | Secondary Prevention

Korea, Republic of, United States, Spain, Canada, Germany, Taiwan, Belgium, Australia, Hong Kong, India, Singapore, Thailand, Greece, Italy, Japan, China, Turkey, Russian Federation, Serbia, Switzerland, Israel, South Africa, Malaysia, Fran... and more
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Terminated

Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
SWOG Cancer Research Network
National Cancer Institute (NCI); Gilead Sciences

Recruiting

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Metastatic HER2 Negative Breast Carcinoma

United States
Tempus AI
GlaxoSmithKline

Active, not recruiting

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Esophageal Cancer | Solid Tumor | Metastatic Cancer | Endometrial Cancer | Urologic Cancer | Breast Tumor | Locally Advanced Solid Tumor | Lung Tumor | Colon Tumor, Malignant

United States
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Stage IV Renal Cell... and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

Melanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditions

United States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland

Clinical Trials on Active Melanoma Brain Metastases in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations